Arrowhead Pharmaceuticals’ RNAi drug plozasiran, brand name Redemplo, is now the second FDA-approved therapy for familial chylomicronemia syndrome, an inherited lipid disorder. Beyond its claims of safety and dosing advantages, Arrowhead set a dramatically lower price for its first commercial product, which will compete against an Ionis Pharmaceuticals drug.
The post With FDA Approval for RNAi Drug, Arrowhead Pharma Starts Price War With Rival Ionis appeared first on MedCity News.
Board-Ready Security Metrics That Actually Matter
TL;DR Board-ready security metrics translate technical capabilities into financial risk and business outcomes. Boards need visibility across three dimensions: risk exposure, incident response capability, and
